Ethyl Acetate → 9-(2-Bromoacetyl)-3,4,7,8-tetrahydro-[1,4]diazepino[7,1-a]isoquinoline-2,5-dione

HRID 926315노트

반응식

HRID 926315 반응식
C([O:3][C:4]([C:6]1[CH:15]=[CH:14][CH:13]=[C:12]2[C:7]=1[CH2:8][CH2:9][N:10]1[C:20](=[O:21])[CH2:19][NH:18][C:17](=[O:22])[CH:16]=[C:11]12)=[CH2:5])C.C1C(=O)N([Br:30])C(=O)C1.CCOC(C)=O>C1COCC1.O.[Cl-].[Na+].O>[Br:30][CH2:3][C:4]([C:6]1[CH:15]=[CH:14][CH:13]=[C:12]2[C:7]=1[CH2:8][CH2:9][N:10]1[C:20](=[O:21])[CH2:19][NH:18][C:17](=[O:22])[CH:16]=[C:11]12)=[O:5]

참가 물질

6

반응물 3

HCID 8857Ethyl AcetateHCID 67184N-bromobutanimideHCID 867113859-(1-Ethoxyvinyl)-3,4,7,8-tetrahydro-[1,4]diazepino[7,1-a]isoquinoline-2,5-dione

생성물 1

HCID 867113869-(2-Bromoacetyl)-3,4,7,8-tetrahydro-[1,4]diazepino[7,1-a]isoquinoline-2,5-dione수율 62.7%

시약·촉매·용매 2

HCID 21881883Oxolane--water (1/1)용매HCID 57417360Sodium chloride; water용매

반응 조건

온도
0 °C

실험 절차

111-2. A solution of 9-(1-ethoxyvinyl)-3,4,7,8-tetrahydro -[1,4]diazepino[7,1-a]isoquinoline-2,5-dione (1.2 g, 4.02 mmol) in a mixture of THF/H2O (3:1, 40 mL) was treated with NBS (716 mg, 4.02 mmol) and the mixture was stirred at 0° C. for 10 min. The mixture was partioned between AcOEt and brine and the org. phase was separated, dried over Na2SO4, filtered and concentrated in vacuo to give the title compound (880 mg) that was used as it is in the next step. UPLC-MS: MS 349.0 (M+H+); UPLC rt 0.69 min.

후처리

  1. customphase was separated
  2. dry with materialdried over Na2SO4
  3. filtrationfiltered
  4. concentrationconcentrated in vacuo

출처 및 근거

ORD 기록
ord-7c0cca5adc6f4c21b17a4e11f53e9e23
출처 데이터셋
uspto-grants-2016_03
특허 번호
US09284331B2

반응 노트

불러오는 중…